UT Southwestern Medical Center is partnering with Pfizer Inc. to develop RNA-enhanced delivery technologies for genetic medicine therapies through the Dallas-based medical center's Genetic Drug Engineering program.

' This collaboration [...] will advance our fundamental understanding of genetic drugs, expand the use of artificial intelligence (AI) design methodologies and lead to the development of new delivery technologies for the creation of potential therapies,' said Daniel Siegwart, professor of biomedical engineering and biochemistry and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.

This agreement is expected to advance UT Southwestern's research and development of cell-targeted nucleic acid and gene-editing therapies that Pfizer could apply to its portfolio of research programs.

Copyright (c) 2024 CercleFinance.com. All rights reserved.